$558.88
18.883.5%
Últ. Act.: Oct 30, 5:48 PM
Vertex Pharmaceuticals (VRTX) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Vertex Pharmaceuticals (VRTX) publicó su última previsión de agosto 3, 2026 para fiscal year 2026. La compañía estimó ingresos en un rango de $13.1B - $13.2B para el período.
En comparación con la previsión anterior, Vertex Pharmaceuticals mantenido redujo su previsión de ingresos desde un rango anterior de $12.95B - $13.1B.
Vertex Pharmaceuticals ha emitido 15 actualizaciones de orientación entre el febrero 7, 2023 y el agosto 3, 2026. During this period, the company raised its outlook 5 times, reflecting management's growing confidence in business performance.
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $4.63 | $4.18 | $4.85 | $4.35 |
| Actual | $4.73 | $4.47 | $5.03 | $4.80 |
| Surprise | +2.16% | +6.94% | +3.71% | +10.3% |
| Revenue | ||||
| Estimate | $3.21B | $2.99B | $3.17B | $3.05B |
| Actual | $3.33B | $2.99B | $3.19B | $3.08B |
| Surprise | +3.74% | -0.24% | +0.54% | +0.80% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $4.67 | $4.52 | $4.49 | $4.65 |
| Revenue | ||||
| Consensus | $3.42B | $3.53B | — | — |
| Trimestre Fiscal | Fecha reportada | EPS real | EPS estimado | Sorpresa % |
|---|---|---|---|---|
| Q2 | Aug 3, 2026 | $4.73 | $4.63 | 2.16 % |
| Q1 | May 4, 2026 | $4.47 | $4.18 | 6.94 % |
| Q4 | Feb 12, 2026 | $5.03 | $4.85 | 3.71 % |
| Q3 | Nov 3, 2025 | $4.80 | $4.35 | 10.3 % |
| Trimestre Fiscal | Fecha reportada | Ingresos reales | Ingresos estimados | Sorpresa % |
|---|---|---|---|---|
| Q2 | Aug 3, 2026 | $3.33B | $3.21B | 3.74 % |
| Q1 | May 4, 2026 | $2.99B | $2.99B | -0.24 % |
| Q4 | Feb 12, 2026 | $3.19B | $3.17B | 0.54 % |
| Q3 | Nov 3, 2025 | $3.08B | $3.05B | 0.80 % |